1 Medical Device Leader's Bright New Hope

Cardiac device maker Boston Scientific has performed well above expectations for investors in 2013. Even with sales in flux, Boston Scientific's stock has more than doubled this year as the firm mitigated hits to its cardiac rhythm management branch while bolstering its investments in emerging technologies.

One of its most promising new markets is atrial fibrillation. This market is expected to boom soon, with research firm Transparency Market Research estimating that the atrial fibrillation market could climb to nearly $15 billion by 2019, with double-digit annual growth. That's the kind of growth that Boston Scientific and its investors would love to capitalize on, and the company's doing its best with its Watchman device for atrial fibrillation.

But will the Watchman perform up to investor hopes? In the video below, Fool contributor Dan Carroll shows how this device is facing its future at the end of this year -- and how Boston Scientific could be on the verge of a major breakthrough.

Can you find the next Boston Scientific?
Looking for the next Boston Scientific to bolster your financial potential? One incredible tech stock is growing twice as fast as Google and Facebook, and more than three times as fast as Amazon.com and Apple. Watch our jaw-dropping investor alert video today to find out why The Motley Fool's chief technology officer is putting $117,238 of his own money on the table, and why he's so confident this will be a huge winner in 2013 and beyond. Just click here to watch!

The article 1 Medical Device Leader's Bright New Hope originally appeared on Fool.com.

Fool contributor Dan Carroll has no position in any stocks mentioned. The Motley Fool owns shares of Medtronic. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Read Full Story